Incidence of cardiovascular adverse events (AEs) in resected non-small cell lung cancer (NSCLC) patients receiving adjuvant platinum-based chemotherapy: a single institution experience from Wythenshawe Hospital, Manchester, UKdoi:10.1016/s0169-5002(20)30129-xJ. Birley...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. PurposeTo study regional differences in lung radiosensitivity by evaluating the incidence of radiation pneumonitis (RP) in relation to regional dose distri... Y Seppenwoolde,KD Jaeger,LJ Boersma,... - ...
AstraZeneca’sImfinzi(durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours...
Following the recent spate of approvals in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the treatment landscape is becoming increasingly difficult to navigate for both physicians and patients, highlighting the need for bette
Figure 2. Annual Incidence of NSCLC (2010-2017) Overall and by Age and Stage View LargeDownload NSCLC indicates non–small cell lung cancer; SEER-18, Surveillance, Epidemiology, and End Results; NPCR, National Program of Cancer Registries. A, NSCLC incidence overall and by age (SEER-NPCR;...
Metastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 ...
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types. Myeloid cells, in particular, are prevalent and have a well-established role in p
: Stage III unresectable locally advanced non-small cell lung cancer (NSCLC) is a complex disease group with poor long-term survival. Clinical data suggests curative intent concurrent chemoradiotherapy (CCRT) is superior to a sequential (SCRT) approach but comes with additional toxicities. We report...